Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it - NPR
Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it NPR
Zepbound News
She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off - Business Insider
She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off Business Insider
When Weight-Loss Drugs Don’t Work - The New York Times
When Weight-Loss Drugs Don’t Work The New York Times
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - CNBC
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market CNBC
US weight-loss drugmakers slash prices in fight to win customers - bbc.com
US weight-loss drugmakers slash prices in fight to win customers bbc.com
A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. - Business Insider
A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. Business Insider
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial - CNBC
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC
Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - The Motley Fool
Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire The Motley Fool
Foundayo, Wegovy and how GLP-1 weight-loss pills compare to shots - USA Today
Foundayo, Wegovy and how GLP-1 weight-loss pills compare to shots USA Today
The new high dose of Wegovy costs less than Zepbound - MarketWatch
The new high dose of Wegovy costs less than Zepbound MarketWatch
Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics - IndexBox
Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics IndexBox
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect Eli Lilly
Pricing and availability of Novo, Lilly's weight-loss drugs - Reuters
Pricing and availability of Novo, Lilly's weight-loss drugs Reuters
Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen - Publix
Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen Publix
GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen - Pharmaceutical Commerce
GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen Pharmaceutical Commerce
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Yahoo Finance
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook Yahoo Finance
Why GLP-1 may not work for some - CNN
Why GLP-1 may not work for some CNN
Multi-Dose KwikPen Now Available for Zepbound Administration - Gastroenterology Advisor
Multi-Dose KwikPen Now Available for Zepbound Administration Gastroenterology Advisor
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide - Business Wire
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide Business Wire
Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare - U.S. News & World Report
Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare U.S. News & World Report
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly
The FDA approves a new obesity pill, giving patients another option - NPR
The FDA approves a new obesity pill, giving patients another option NPR
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC
Zepbound Blindness Lawsuit [2026 Update] - robertkinglawfirm.com
Zepbound Blindness Lawsuit [2026 Update] robertkinglawfirm.com
Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month - Bloomberg.com
Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month Bloomberg.com
Here’s how much weight-loss drugs Wegovy, Zepbound and Foundayo cost — and how to pick the best GLP-1 for you - MarketWatch
Here’s how much weight-loss drugs Wegovy, Zepbound and Foundayo cost — and how to pick the best GLP-1 for you MarketWatch
Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable - The Independent
Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable The Independent
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management - Yahoo Finance
Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management Yahoo Finance
Everyone Wants This Unapproved Weight Loss Drug—And Some Have Found a Way to Get It - SELF Magazine
Everyone Wants This Unapproved Weight Loss Drug—And Some Have Found a Way to Get It SELF Magazine
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity - HCPLive
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity HCPLive
Eli Lilly launches Zepbound KwikPen on Ro (LLY:NYSE) - Seeking Alpha
Eli Lilly launches Zepbound KwikPen on Ro (LLY:NYSE) Seeking Alpha
Never before seen: State investigators raiding a Kirkland Pharmacy that makes weight loss drugs - KREM
Never before seen: State investigators raiding a Kirkland Pharmacy that makes weight loss drugs KREM
Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs - Memorial Sloan Kettering Cancer Center
Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs Memorial Sloan Kettering Cancer Center
Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? - Everyday Health
Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? Everyday Health
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know - Good Morning America
Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know Good Morning America
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study CNBC
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - CNBC
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site CNBC
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight Eli Lilly